INTRODUCTION: Patients with advanced Parkinson's disease (PD) often develop motor complications including fluctuations and involuntary movements (dyskinesias). In Denmark, treatment has comprised Deep Brain Stimulation (DBS) since the late 1990s, and as from 2002 use of a subcutaneous apomorphine pump. Monotherapy with continuous intestinal levodopa infusion to the duodenum (Duodopa) was introduced in 2004. MATERIAL AND METHODS: A total of 14 PD patients were assessed for Duodopa pump therapy in the 2004-2008 period. After an initial test week, 12 of the patients had a permanent percutaneous endoscopic gastrostomy (PEG) tube inserted containing a smaller intestinal tube terminating in the duodenum. Before and after treatment initiation, we evaluated the patients using clinical rating scales and video recordings. RESULTS: Objectively, all 12 patients experienced a significant reduction in fluctuations and dyskinesias while achieving a better gait function. Three patients received Duodopa as 24-hour treatment with good effect on severe nocturnal dystonic pain. One patient suffered a severe complication (peritonitis). CONCLUSION: Duodopa has a symptom-relieving and stabilizing effect without side effects, but entails a risk of surgical complications (peritonitis).
INTRODUCTION:Patients with advanced Parkinson's disease (PD) often develop motor complications including fluctuations and involuntary movements (dyskinesias). In Denmark, treatment has comprised Deep Brain Stimulation (DBS) since the late 1990s, and as from 2002 use of a subcutaneous apomorphine pump. Monotherapy with continuous intestinal levodopa infusion to the duodenum (Duodopa) was introduced in 2004. MATERIAL AND METHODS: A total of 14 PDpatients were assessed for Duodopa pump therapy in the 2004-2008 period. After an initial test week, 12 of the patients had a permanent percutaneous endoscopic gastrostomy (PEG) tube inserted containing a smaller intestinal tube terminating in the duodenum. Before and after treatment initiation, we evaluated the patients using clinical rating scales and video recordings. RESULTS: Objectively, all 12 patients experienced a significant reduction in fluctuations and dyskinesias while achieving a better gait function. Three patients received Duodopa as 24-hour treatment with good effect on severe nocturnal dystonic pain. One patient suffered a severe complication (peritonitis). CONCLUSION:Duodopa has a symptom-relieving and stabilizing effect without side effects, but entails a risk of surgical complications (peritonitis).
Authors: Mechelle M Lewis; Guangwei Du; Michal Kidacki; Nisargkumar Patel; Michele L Shaffer; Richard B Mailman; Xuemei Huang Journal: Neurobiol Aging Date: 2012-11-21 Impact factor: 4.673
Authors: Maria José Catalán; Angelo Antonini; Matilde Calopa; Ovidiu Băjenaru; Oriol de Fábregues; Adolfo Mínguez-Castellanos; Per Odin; José Manuel García-Moreno; Stephen W Pedersen; Zvezdan Pirtošek; Jaime Kulisevsky Journal: eNeurologicalSci Date: 2017-07-02
Authors: Sandeep Thakkar; Victor S C Fung; Aristide Merola; Meredith Rollins; Michael J Soileau; Norbert Kovács Journal: CNS Drugs Date: 2021-02-13 Impact factor: 5.749
Authors: Tove Henriksen; Kim Peder Dalhoff; Henriette Engel Hansen; Andreas W Brenneche; Ulla Sofie Lønberg; Erik Hvid Danielsen Journal: Mov Disord Clin Pract Date: 2020-07-02
Authors: Tomasz Fundament; Paul R Eldridge; Alexander L Green; Alan L Whone; Rod S Taylor; Adrian C Williams; W M Michael Schuepbach Journal: PLoS One Date: 2016-07-21 Impact factor: 3.240
Authors: James T Boyd; Cindy Zadikoff; Janet A Benesh; Jorge Zamudio; Weining Z Robieson; Pavnit Kukreja; Masayuki Yokoyama; Mustafa S Siddiqui Journal: Clin Park Relat Disord Date: 2019-12-11